CD66e Blocking Antibody for Enhanced Immune Research and Diagnostics

Alpha Lifetech Incorporation presents a cutting-edge CD66e blocking antibody, designed to advance your research in immunology and cell biology. CD66e, also known as CEACAM6, plays a crucial role in cell adhesion, immune response modulation, and tumor progression. Our high-quality blocking antibody provides exceptional specificity and sensitivity, enabling researchers to effectively study the functions and mechanisms of CD66e in various biological contexts, This versatile tool is ideal for applications such as flow cytometry, immunohistochemistry, and western blotting, making it an essential addition to your laboratory. By blocking CD66e interactions, you can gain deeper insights into its role in cancer biology and immune evasion, potentially leading to novel therapeutic targets, With rigorous quality control and validation, Alpha Lifetech’s CD66e blocking antibody ensures reliable and reproducible results. Elevate your research with this innovative product and unlock new pathways in the understanding of immune mechanisms and cancer therapy

Hot Selling Product

ADT1051-Arcitumomab Biosimilar-Anti-CEACAM5/CD66e mAb-Research Grade

ADT1567-RSV-neutralizing Human Antibody (D25) Biosimilar-(RSV)-Research Biosimilar Antibody

ADT1006-Abelacimab Biosimilar (F11)-Research Biosimilar Antibody

ADT1745-Human Anti-CD3ExCD20 Bispecific Antibody

ADT1746-Human Anti-CD3ExBCMA Bispecific Antibody

Why Trust cd66e blocking antibody For the Current Year Factory

In the dynamic landscape of biotechnological advancements, having reliable tools for research and development is paramount. This is where the cd66e blocking antibody from Alpha Lifetech Inc. stands out as an invaluable asset for scientists and researchers across the globe. With a foundation built by a team of scientists specializing in membrane Protein production and monoclonal development, Alpha Lifetech has consistently delivered high-quality reagents tailored for diverse applications. The cd66e blocking antibody is meticulously developed to target CD66e, a critical marker involved in immune responses, making it essential for studies related to cancer immunology and infectious diseases. This year, as laboratories worldwide ramp up their efforts in drug discovery and development, the importance of dependable and effective antibodies cannot be understated. Alpha Lifetech Inc. boasts nearly 10,000 premium reagents, including potent cytokines and drug target antibodies, ensuring that researchers have the tools necessary to drive their projects forward. By trusting the cd66e blocking antibody, procurement professionals and researchers can gain confidence in their experimental outcomes, knowing they are backed by a company with extensive experience and a commitment to quality. Choosing Alpha Lifetech’s cd66e blocking antibody means investing in your research with a partner dedicated to excellence in biotechnological products. Our commitment to quality and innovation, combined with our scientists' expertise, positions us as a trusted provider for the current year's laboratory needs. With Alpha Lifetech, you're not just purchasing a reagent; you’re ensuring the integrity and success of your research endeavors. Embrace the future of biopharmaceutical research with our top-tier solutions.

Why Trust cd66e Blocking Antibody For the Current Year Factory

Specification	Details	Applications	Research Findings
Clone ID	cd66e-123	FACS, IHC	Effective in blocking cd66e interactions in various cell types.
Host Species	Rabbit	Western Blot, ELISA	Demonstrated high specificity and low cross-reactivity.
Purity	>95%	Immunoprecipitation	Supported by multiple studies on cancer cell lines.
Storage	-20°C	Cell Signaling	Capsulated efficacy in biological assays.
Shelf Life	12 months	Tissue Studies	Proven stability under recommended storage conditions.

Trends in Antibody Usage Across Different Research Fields (2023)

This chart highlights the trends in antibody usage across three major research fields: Immunology, Molecular Biology, and Cell Biology for the year 2023. The data demonstrates a significant increase in the adoption of antibodies, particularly within the Immunology sector, which shows a steady month-to-month rise. Particularly, there has been a dramatic surge post mid-year, indicating heightened research activity. Molecular Biology follows closely, although it shows a more subdued gain over the months. Cell Biology, while showing growth, has had the slowest increase among the three fields, reflecting possibly different research focuses or funding opportunities. The visual representation of these trends aids researchers in understanding which fields are currently experiencing a boon in antibody applications, guiding future purchasing decisions and research planning.